Amgen’s Imdelltra Wins FDA Nod In Underserved SCLC Population
The DLL3-targeting bispecific antibody won accelerated approval in extensive-stage small-cell lung cancer among patients treated with platinum chemotherapy.
The DLL3-targeting bispecific antibody won accelerated approval in extensive-stage small-cell lung cancer among patients treated with platinum chemotherapy.